ISLAMABAD (PEN) : A recent study published in JAMA Ophthalmology suggests that patients using Novo Nordisk’s drugs like Wegovy for weight loss and semaglutide for type 2 diabetes may face an increased risk of a sight-threatening eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). The research found higher rates of NAION among those using semaglutide compared to other medications, with significantly elevated risks observed in both diabetes and obesity treatment groups. Novo Nordisk has noted limitations in the study design and emphasizes that the data does not establish a definitive causal link between their drugs and NAION.
© 2024 – Pakistan Economic NET. All Rights Reserved.
Developed by Optimaxor